R&D Update

November 2007
PharmaWatch: CNS;Nov2007, Vol. 6 Issue 11, p10
Market Research Report
The article offers news briefs related to pharmaceutical industry worldwide in 2007. Adlea is a long-acting, non-opiate analgesic drug which designed for weeks to months pain relief in single local dose during the surgical procedure. Australian company Phosphagenics has received approval to start its Phase I clinical trial directed at delivering the pain relief drug, oxycodone, through the skin.


Related Articles

  • Phosphagenics working on topical opioid patch.  // Australian Life Scientist;Mar/Apr2013, Vol. 10 Issue 2, p6 

    The article informs that Phosphagenics Ltd. has included an oxycodone-based patch designed for local pain relief in its pain patch portfolio and is also planning to start clinical trials of a similar version of the patch in the third quarter.

  • POSITIVE RESULTS FROM PHASE 1B OF OXYCODONE PATCH.  // Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p1 

    The article reports on the positive results of the Phase 1B clinical study conducted by Phosphagenics Ltd. using its Targeted Penetration Matrix (TPMâ„¢) for the transdermal delivery of oxycodone. The trial has successfully demonstrated that daily application of a TPMâ„¢-oxycodone patch...

  • Monetising a platform technology. Ogru, Esra // Australasian Biotechnology;Oct2011, Vol. 21 Issue 3, p30 

    This sector is acutely aware of the squeeze on Australian companies in raising ongoing capital. Phosphagenics is implementing a range of strategies to reduce the need to return to the market for capital. Phosphagenics' primary goal is to develop a transdermal oxycodone patch. A successfully...

  • CLINICAL TRIALS NEWS.  // Applied Clinical Trials;Jun2007, Vol. 16 Issue 6, p30 

    The article offers news briefs related to clinical trials. Paris, France-based NicOx SA has begun its second Phase III naproxcinod trial to verify the effectiveness of the drug. Sydney, New South Wales-based Alchemia Lid. has completed its Phase II study comparing its product HyCAMP with...

  • QRxPharma kicks off pivotal trial for MoxDuo.  // Australian Life Scientist;12/2/2009, p2 

    Phase III trial for MoxDuo IR in the U.S. with final trial to begin in 2010.

  • TPM/OXYCODONE PATCH TRIAL RECEIVES ETHICS APPROVAL.  // Biotech Business;Jan2015, Vol. 28 Issue 1, p2 

    The article reports that biotechnology company Phosphagenics Ltd. has earned ethics approval for the commencement of proof of concept Phase 2 trial in Australia for its TPM/Oxycodone patch. Topics discussed include the trial's goal of determining the effectiveness of the patch for lessening the...

  • CLINIC ROUNDUP.  // BioWorld Today;12/16/2013, Vol. 24 Issue 240, p8 

    This section highlights the results of clinical trials of various medications being developed by multinational pharmaceutical companies as of December 2013. For instance, the findings of a Phase II study indicated that AcelRx Pharmaceuticals' sublingual product candidate ARX-04 was proven...

  • NeurogesX Presents Positive Pain Patch Data.  // Bioworld Week;6/11/2007, Vol. 15 Issue 24, p5 

    The article reports on the plans of NeurogesX Inc. to seek first approval for its phase III trial of the pain patch in treating possible neuralgia in Europe. The 402-patient study of NGX-4010 showed a significant pain relief versus a control path. The positive study on postherpetic neuralgia...

  • Data Slice and Dice. Henderson, Lisa // Applied Clinical Trials;Jan2010, Vol. 19 Issue 1, p12 

    An introduction to the journal is presented in which the editor discusses the aspects of Applied Clinical Trials, one on clinical trials conducted by pharmaceutical companies, and the launching of e-newsletters that explore cardiac safety and oncology trials.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics